Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.

ABSTRACT: Checkpoint molecules such as programmed death 1 (PD-1) dampen excessive T cell activation to preserve immune homeostasis. PD-1-specific monoclonal antibodies have revolutionized cancer therapy, as they reverse tumour-induced T cell exhaustion and restore CTL activity. Based on this success, deciphering underlying mechanisms of PD-1-mediated immune functions has become an important field of immunological research. Initially described for T cells, there is emerging evidence of unconventional PD-1 expression by myeloid as well as tumor cells, yet, with cell-intrinsic functions in various animal tumor models. Here, we describe positive PD-1 antibody staining of various murine immune and tumour cells that is, unlike for T cells, not the PD-1 receptor and restricted to cells with low forward sca

SUBMITTER: Metzger P 

PROVIDER: S-EPMC5995819 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature